Acadian Asset Management LLC Acquires 63,349 Shares of Design Therapeutics, Inc. $DSGN

Acadian Asset Management LLC boosted its stake in Design Therapeutics, Inc. (NASDAQ:DSGN) by 11.2% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 630,953 shares of the company’s stock after buying an additional 63,349 shares during the quarter. Acadian Asset Management LLC owned approximately 1.11% of Design Therapeutics worth $2,434,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Woodline Partners LP bought a new stake in shares of Design Therapeutics during the first quarter valued at approximately $2,492,000. Point72 Asset Management L.P. grew its position in shares of Design Therapeutics by 16.0% during the fourth quarter. Point72 Asset Management L.P. now owns 1,856,750 shares of the company’s stock worth $11,456,000 after purchasing an additional 256,010 shares in the last quarter. Nuveen LLC bought a new position in Design Therapeutics during the first quarter valued at approximately $568,000. Wellington Management Group LLP bought a new stake in shares of Design Therapeutics in the 1st quarter valued at approximately $546,000. Finally, Driehaus Capital Management LLC lifted its stake in shares of Design Therapeutics by 17.7% in the 1st quarter. Driehaus Capital Management LLC now owns 913,399 shares of the company’s stock valued at $3,526,000 after purchasing an additional 137,317 shares during the last quarter. Institutional investors own 56.64% of the company’s stock.

Design Therapeutics Stock Performance

Shares of NASDAQ DSGN opened at $5.86 on Tuesday. The business’s 50 day moving average price is $4.83 and its 200-day moving average price is $4.25. The company has a market cap of $333.73 million, a price-to-earnings ratio of -5.23 and a beta of 1.61. Design Therapeutics, Inc. has a fifty-two week low of $2.60 and a fifty-two week high of $7.77.

Design Therapeutics (NASDAQ:DSGN) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.02). Sell-side analysts predict that Design Therapeutics, Inc. will post -0.91 earnings per share for the current year.

Design Therapeutics Company Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.